Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumonia

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to compare the median exposures at pharmacokinetic equilibrium of the two modalities of administration: 4-hours infusion of ceftolozane-tazobactam at a dosage of 2 gram three times a day vs 1-hour infusion of 2 gram three times a day.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Toulouse
• Treatments: Ceftolozane, tazobactam drug combination; Cephalosporins; Penicillanic Acid; Pharmaceutical Solutions; Tazobactam

Criteria

inclusion criteria

• patients with ventilator associated-pneumonia to Pseudomonas aeruginosa

• patients hospitalized in intensive care units

• Pseudomonas aeruginosa susceptible to ceftolozane-tazobactam

• Simplified Acute Physiological Score II (SAPS II () > 20

• Expected duration of survival > 7 days

• Informed consent of the patient or, failing that, the patient's close or trustworthy person

• Affiliated to a social security scheme or equivalent

Non inclusion criteria:

• history of allergy to one of the two molecules

• history of allergy to betalactamines

• Strain Isolated resistant to Ceftolozane-Tazobactam combination

• Renal insufficiency with a glomerular filtration rate evaluated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) < 50 ml/min

• Patient on dialysis or under continuous hemodiafiltration

• pregnant or nursing women

• patient benefiting from a system of legal protection for adults

• patient with active immunodepression.